Designing around viral resistance

Resistance of HIV to both protease inhibitors and reverse transcriptase inhibitors has become a huge problem for the clinical management of AIDS, stimulating the search for inhibitors of these enzymes that are not made clinically useless by viral evolution.

Last week, Tibotec N.V. reported that its approach

Read the full 462 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE